Advanced Accelerator Applications

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

Retrieved on: 
Friday, March 25, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Garching (Munich U-Bahn), Therapy, Nuclear medicine, Leadership, III, Diagnosis, Radiopharmaceutical, BIC, ITM, Adult, CFO, PSMA, Neoplasm, Novartis, Cancer, Board of directors, Commercial, Achievement, Food, CEO, IBAN, Advanced Accelerator Applications, Food and Drug Administration, Taxane, Supervisory board, MCRPC, FDA, VAT, Radionuclide, Patient, Radiation, Medical imaging, EU, TARGETED RADIONUCLIDE THERAPY, ITM ISOTOPE TECHNOLOGIES MUNICH SE

177Lu (EndolucinBeta), a core component of the newly approved radiotherapeutic, for the commercial phase based on a supply agreement entered in 2020, supporting the scalability and security-of-supply for patients worldwide.

Key Points: 
  • 177Lu (EndolucinBeta), a core component of the newly approved radiotherapeutic, for the commercial phase based on a supply agreement entered in 2020, supporting the scalability and security-of-supply for patients worldwide.
  • lutetium-177 for Pluvicto, we share in the excitement of this approval, commented Steffen Schuster, Chief Executive Officer of ITM.
  • We congratulate Advanced Accelerator Applications on its notable achievement and are proud to have contributed clinical supply for the development of this new therapeutic.
  • ITM has established an industrial scale production of high-quality n.c.a.

Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth

Retrieved on: 
Thursday, February 17, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, ISCB Senior Scientist Award, NIBR, Ministry of Education (Malaysia), Patient, Family, Biomedical Research, Cancer, NAD, Takeda Oncology, Scripps Research, Biotechnology, Company, Inflammation, Science, Achievement, SCCL, Enzyme, Lung, R, Business development, Coronavirus Scientific Advisory Board (Turkey), Therapy, Institute, SAB, Partnership, Biology, BD, Novartis Institute for Tropical Diseases, Advanced Accelerator Applications, Medicine, Board, Flagship Pioneering, Disease, Research, Multimedia, Medicinal chemistry, History of Indian Institutes of Technology, Program, University, Management, Pharmaceutical industry, Technology, Novartis, Director

On behalf of the Board of Directors, I sincerely thank Vicky for her many contributions to the Company.

Key Points: 
  • On behalf of the Board of Directors, I sincerely thank Vicky for her many contributions to the Company.
  • I look forward to a collaborative and productive relationship with Vicky and the organization at Ribon to shepherd the company through its next phase of growth.
  • I am pleased to welcome Prakash to Ribon at this important time for the Company, said Dr. Richon.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors

Retrieved on: 
Thursday, February 3, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Diamond, Growth, Advanced Accelerator Applications, Leadership, Faculty, Radiobiology, American Board of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Therapy, Elgin Mental Health Center, MBBS, Roche, PSMA, Cancer, Hematology, Indiana University School of Medicine, University, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Clinical research, Medicine, Emory University School of Medicine, Board, Board of directors, Ministry of Education (Malaysia), Radiopharmaceutical, Radiochemistry, Industry, Oncology, YM Biosciences, Eli Lilly, Curie, Pharmaceutical industry

Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors.

Key Points: 
  • Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors.
  • I am excited to welcome Kapil to our Board of Directors, said Simon Read, Curies CEO and Founder.
  • Its an honor to join Curies Board of Directors, said Dr. Dhingra.
  • Dr. Dhingra serves on the Boards of Directors of Lava Therapeutics (as Chairman of the Board), Black Diamond Therapeutics, Inc., Replimune, Inc., Median Technologies, and Autolus Therapeutics plc.

Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA

Retrieved on: 
Tuesday, January 25, 2022
TLX, Food, Political science, Gallium, TGA, MTR, Advanced Accelerator Applications, LinkedIn, Radiation, Ministry of Education (Malaysia), AAA, Time, EMEA, Company, Cancer, Patient, Marketing, MBA, Degenerative disease, Alumnus, Australian Securities Exchange, ASX, GLOBE, FDA, Pharmaceutical industry, Animal, Telix

MELBOURNE, Australia and LIGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Raphal Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).

Key Points: 
  • MELBOURNE, Australia and LIGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Raphal Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).
  • Raphal joins Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia.
  • On joining Telix Raphal stated, Molecularly targeted radiation is progressively becoming a mainstream oncology solution.
  • Telix EMEA President, Richard Valeix added, It is a great pleasure to welcome Raphal to the team at this important moment in the Companys evolution.

Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer's Disease and Brain Pathologies

Retrieved on: 
Tuesday, December 21, 2021
Doctor of Philosophy, Exercise, Steroid dementia syndrome, AD, Patent, Advanced Accelerator Applications, TEL, Method, Disease, Application server, Multiple sclerosis, Stroke, United States Patent and Trademark Office, USPTO, Patient, Traumatic brain injury, Medical imaging, Alzheimer's disease

TEL AVIV, Israel, Dec. 21, 2021 /PRNewswire/ -- Ixtlan Bioscience , a biotech company focused on developing psilocybin-based treatment for Alzheimer's Disease and Brain Pathologies, has announced today the filing of a new Provisional Patent with the United States Patent and Trademark Office (USPTO) Application No.

Key Points: 
  • TEL AVIV, Israel, Dec. 21, 2021 /PRNewswire/ -- Ixtlan Bioscience , a biotech company focused on developing psilocybin-based treatment for Alzheimer's Disease and Brain Pathologies, has announced today the filing of a new Provisional Patent with the United States Patent and Trademark Office (USPTO) Application No.
  • 63279349 named; Ixtlan AD Kit, which is a novel treatment for Alzheimer's and neuronal disorders.
  • "We are pleased to announce this new provisional patent filing for Alzheimer's Disease and brain pathologies, which is very important for the development of our novel and proprietary Ixtlan AD Kit, for at-home treatment of patients suffering from Alzheimer's and other dementia diseases," commented Yehonatan Cavens, chief finance officer of Ixtlan Bioscience.
  • Ixtlan Bioscience is focused on developing its novel and proprietary Ixtlan AD Kit, for the at-home treatment of patients suffering from Alzheimer's and dementia diseases.

Advancements Series to Explore Breakthroughs in Biopharmaceutical Technology

Retrieved on: 
Thursday, December 9, 2021
Technology, DMG, Quality of life, Cancer, Patient, CEO, Advanced Accelerator Applications, Education, CCT, Diagnosis, Prognosis, Medical imaging

JUPITER, Fla., Dec. 9, 2021 /PRNewswire-PRWeb/ --Scheduled to broadcast spring/2022, Advancements with Ted Danson will focus on cutting-edge biomedical technologies for cancer metastasis care.

Key Points: 
  • JUPITER, Fla., Dec. 9, 2021 /PRNewswire-PRWeb/ --Scheduled to broadcast spring/2022, Advancements with Ted Danson will focus on cutting-edge biomedical technologies for cancer metastasis care.
  • Hearing from experts in the field, viewers will learn about recent developments in biopharmaceutical technologies.
  • "Cellmig uses CCT marker protein-based molecular biomedicine technologies to produce precise and effective diagnosis kits and cancer drugs.
  • About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Thursday, November 11, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Medical Devices, American Academy of Ophthalmology, Industry, Cross-link, Refraction, Security (finance), Complication, Advanced Accelerator Applications, Technology, Cornea, Keratoconus, GKOS, AAO, Retina, American Academy, Glaucoma, U.S. Securities and Exchange Commission, Customization, SEC, NYSE, Corporation, MIGS, Phacoemulsification, Glaucoma surgery, Pharmaceutical industry, Risk management, Birth control

SMILE Combined with Accelerated Cross-Linking

Key Points: 
  • SMILE Combined with Accelerated Cross-Linking
    Visual and Refractive Outcomes and Complications of Customized PRK Plus Accelerated Cross-Linking in Early Keratoconus vs.
  • Customized LASEK in Myopic Subjects
    Glaukos will also be exhibiting on the showroom floor throughout AAO at booth #4015.
  • The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, November 2, 2021
Science, Ionis Pharmaceuticals, Research, Chemistry, Actinium, Biochemistry, Industry, Neoplasm, Drug development, Merck, DNA, Financial compensation, FGFR3, Partnership, Patient, TAT, Radiopharmaceutical, View, Drug discovery, Ministry of Education (Malaysia), Baldwin Wallace University, GMP, PSMA, Neurotensin receptor, Company, McMaster University, Investment, Isotope, Tat, Multimedia, Board, IND, Program, NTSR1, Acquisition, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Advanced Accelerator Applications, Good manufacturing practice, AstraZeneca, Therapy, Employment, GlaxoSmithKline, Pembrolizumab, Purdue University, Pharmaceutical industry

HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.

Key Points: 
  • HAMILTON, OntarioandBOSTON, Nov. 2, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer.
  • Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.
  • Prior to Novartis, he was vice president, discovery research at Advanced Accelerator Applications, a subsidiary acquired by Novartis in 2018.
  • Eric Burak, Ph.D., Fusion's chief scientific officer since the company's inception, has been appointed chief technology officer.

Dalton Pharma Services Partnership with TransMedics for their OCS Liver Transplantation System

Retrieved on: 
Tuesday, October 26, 2021
Lung, Transplant, Technology, CDMO, History, Patient, CGMP, Drug discovery, FDA, Health Canada, Perfusion, OCS, Transmedics, API, Solution, Liver transplantation, Advanced Accelerator Applications, Liver failure, Powder, Heart, Fine chemical, Pharmaceutical industry, Dentistry

TORONTO, Oct. 26, 2021 /PRNewswire-PRWeb/ -- Dalton Pharma Services, a leading North American Pharmaceutical cGMP CDMO is pleased to announce our manufacturing agreement with TransMedics Group, Inc. for their OCS Liver System.

Key Points: 
  • TORONTO, Oct. 26, 2021 /PRNewswire-PRWeb/ -- Dalton Pharma Services, a leading North American Pharmaceutical cGMP CDMO is pleased to announce our manufacturing agreement with TransMedics Group, Inc. for their OCS Liver System.
  • TransMedics was recently granted FDA premarket approval for their OCS Liver System that will be used on organs from donors.
  • Peter Pekos CEO of Dalton Pharma Services said "we are excited to be supporting TransMedics by providing powder filling services in the manufacture of their transformative products which will significantly benefit patients".
  • TransMedics President and CEO Waleed Hassanein says "TransMedics is now uniquely positioned to offer its OCS perfusion technology for lung, heart, and liver transplantation.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting

Retrieved on: 
Thursday, October 7, 2021
Health, Medical Devices, Surgery, Research, Science, Pharmaceutical, Optical, Retina, Small incision lenticule extraction, Standard of care, Cataract, Patient, GKOS, Doctor of Philosophy, Siena, Rerun, Physician, Industry, Glaucoma, SEC, European Society for Medical Oncology, Relex, MD, Standard, U.S. Securities and Exchange Commission, Extra, Glaucoma surgery, CURV, Moderate, Advanced Accelerator Applications, Security (finance), Effect, MIGS, Keratoconus, Corporation, Cross-link, NYSE, CEST, Trabecula, Quality of life, Technology, Annual general meeting, Pharmaceutical industry, Animal

The ESCRS annual meeting is among the largest global gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.

Key Points: 
  • The ESCRS annual meeting is among the largest global gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.
  • All educational content of the ESCRS annual meeting is planned by its program committee, and ESCRS does not endorse, promote, approve or recommend the use of any products, devices or services.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.